About the journal
Cancer Biology & Medicine is an open-access journal published by China Anti-Cancer Association in China, publishing in english. It is listed in DOAJ and MEDLINE and PUBMED according to the sources read. Declared publication charge: 2,800 USD. Declared review time at DOAJ: 12 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- China Anti-Cancer Association
- ISSN
- 2095-3941
- Country
- China
- Languages
- english
- Access
- Open access
- Declared publication charge
- 2,800 USD
- Articles in DOAJ
- 1222
- Declared review time
- 12 weeks
- Declared peer-review model
- peer_review
- Official website
- https://www.cancerbiomed.org/
Index listings
- DOAJ · 2019-02-25
- MEDLINE · 2020-01-01
- PUBMED · 2020-02-15
- Indexing
- DOAJ · MEDLINE · PUBMED
- APC
- 2,800 USD
- Declared review time (DOAJ)
- 12 weeks — journal-declared only (not measured)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Articles in DOAJ
1222
Most recent article
last month
Average review time (journal-declared via DOAJ)
12weeks
Works in OpenAlex
944
Last recorded publication year
2026
h-index
70
i10-index
473
From OpenAlex open data (CC0).
Editorial & policy9
- Last DOAJ review date
- 2024-04-11
- Added to DOAJ
- 2019-02-25
- Declared plagiarism screening
- Not declared
- Other fees beyond APC
- No
- Declared digital preservation
- PMCScholars portal
- Editorial board
- Official page ↗
- Open references deposited at Crossref
- 0%
- ORCID iDs in current deposits
- 96%
- Peer-review policy
- View policy
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 101588850
Classification2
Subjects (DOAJ)
LCC codes
Subject areas
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Cancer Genomics and Diagnostics
- Immunotherapy and Immune Responses
- Immunotherapy and Immune Responses
- Ferroptosis and cancer prognosis
- Ferroptosis and cancer prognosis
Show all subjects (50)
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Immune cells in cancer
- Cancer Cells and Metastasis
- Cancer Cells and Metastasis
- CAR-T cell therapy research
- CAR-T cell therapy research
- Cancer-related molecular mechanisms research
- Cancer-related molecular mechanisms research
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Hepatocellular Carcinoma Treatment and Prognosis
- Immune Cell Function and Interaction
- Immune Cell Function and Interaction
- RNA modifications and cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- RNA modifications and cancer
- Breast Cancer Treatment Studies
- Breast Cancer Treatment Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Pancreatic and Hepatic Oncology Research
- Lung Cancer Research Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cholangiocarcinoma and Gallbladder Cancer Studies
- MicroRNA in disease regulation
- Epigenetics and DNA Methylation
- Epigenetics and DNA Methylation
- MicroRNA in disease regulation
- Cancer Research and Treatments
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- Nanoplatforms for cancer theranostics
- Gastric Cancer Management and Outcomes
- Gastric Cancer Management and Outcomes
- Glioma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Glioma Diagnosis and Treatment
- Nanoparticle-Based Drug Delivery
- Nanoparticle-Based Drug Delivery
Keywords (DOAJ)
- cancer genetics
- oncology clinical trials
- targeted therapy and immunology
- cancer and stem cell biology
- cancer prevention and epidemiology
- cancer biomarkers
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
The journal's record in other sources:Web of Science MJLDOAJ